Last Price
131.19
Today's Change
+0.963 (0.73%)
Day's Change
129.40 - 131.56
Trading Volume
160,460
Market Cap
14 Billion
Shares Outstanding
125 Million
Avg Volume
808,389
Avg Price (50 Days)
127.44
Avg Price (200 Days)
131.99
PE Ratio
41.45
EPS
2.78
Earnings Announcement
31-Jul-2023
Previous Close
116.30
Open
115.98
Day's Range
114.67 - 117.21
Year Range
113.17 - 170.0
Trading Volume
1,633,024
1 Day Change
0.00%
5 Day Change
0.00%
1 Month Change
-0.91%
3 Month Change
-6.55%
6 Month Change
-19.81%
Ytd Change
-18.35%
1 Year Change
-16.58%
3 Year Change
17.27%
5 Year Change
47.10%
10 Year Change
248.79%
Max Change
8140.26%
No result.
Sector: Healthcare - Healthcare
Industry: Diagnostics & Research
Description:
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.